REUTERS - Ranbaxy Laboratories , India's top drugmaker by sales, reported a net loss of 5.24 billion rupees for the June quarter on foreign exchange transactions and loss of goodwill booked at its overseas subsidiaries.
Ranbaxy, controlled by Japan's Daiichi Sankyo Co , had reported a net loss of 5.86 billion rupees for the same period last year.
Sales fell 17.84 percent to 26.33 billion rupees during fiscal second quarter ended June, the drugmaker said on Wednesday.
The company recorded foreign exchange losses of 3.67 billion rupees while it booked a loss of goodwill worth 1.19 billion rupees at its overseas subsidiaries, it said in a filing to the Bombay Stock Exchange.
Analysts, on an average, had estimated net profit of 335.56 million rupees, according to Thomson Reuters I/B/E/S.
Shares in Ranbaxy ended up 4.32 percent at 281.50 rupees on Wednesday when the BSE Sensex fell 0.36 percent.
(Reporting by Kaustubh Kulkarni in MUMBAI; Editing by Anupama Dwivedi)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
